Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Clinical Trials: Around Half of… >
Clinical Trials: Around Half of New Treatments Perform Better Than Existing Treatments

Published: October 17, 2012.
By Wiley
http://www.wiley.com/wiley-blackwell

On average, new treatments perform better in clinical trials only slightly more often than existing treatments, according to a new systematic review published in The Cochrane Library. The fact that experimental treatments are not more effective may seem disappointing, but the authors of the review say their findings satisfy an important ethical requirement for clinical trials.

Randomised trials compare the effects of one treatment to another. In a randomised trial patients are randomly allocated to different treatment groups to ensure that like will be compared with like. When a new treatment is being tested, it is hoped or even expected that it will be better than the established treatment with which it is being compared. These expectations lead to an ethical dilemma. If the researchers already know that one treatment is better, they would be knowingly allocating some people to an inferior treatment. If randomised trials are to be ethical, therefore, only half of new treatments should turn out to be better than existing ones.

Cochrane researchers looked at evidence from 743 publicly funded randomised trials involving 297,744 patients in total. The trials included new, experimental treatments for cancer and neurological disorders, as well as a range of other diseases. On average, only very slightly more than half of new treatments proved to be better than established treatments.

"When we compared the effects of new treatments to established ones, the pattern was almost symmetrical. This is good news, because it means researchers genuinely don't know whether new treatments are going to be any better," said lead researcher Benjamin Djulbegovic, who works at USF Health Clinical Research, and the H. Lee Moffitt Cancer Center & Research Institute, at the University of South Florida in Tampa, Florida, US. "So, overall, what we show is that we can expect the new treatments to perform better a little bit more often than established treatments, at least in publicly funded trials like the ones we considered."

The researchers found the same pattern in trials going back five decades. The results provide an answer to the question posed 15 years ago in the British Medical Journal by Iain Chalmers, a founder of the Cochrane Collaboration and one of the authors of the review. "In 1997, in a letter published in the BMJ, I asked 'What is the prior probability of a proposed new treatment being superior to established treatments?' I think this review currently provides the best answer to that question," said Chalmers.




Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
All comments are reviewed before being posted. We cannot accept messages that refer a product, or web site.If you are looking for a response to a question please use our another feedback page.
Related »

Patients 
8/27/13 
New Treatments Better Than Standard Ones Just over Half the Time
By University of South Florida (USF Health)
Tampa, FL (August 27, 2013) -- University of South Florida Distinguished Professor Benjamin Djulbegovic, MD, PhD, has studied the ethics of randomized clinical trials and their effectiveness in evaluating …
Adherence 
11/20/14 
★★★★ 
Only Half of Patients Take Their Medications as Prescribed
By Wiley
The cost of patients not taking their medications as prescribed can be substantial in terms of their health. Although a large amount of research evidence has tried to address …
Trials 
9/11/12 
★★★★ 
Interventions Can Reduce Falls in People over 65 Who Live at Home
By Wiley
There is now strong evidence that some interventions can prevent falls in people over the age of 65 who are living in their own homes. However, the researchers who …
Understand 
10/15/14 
EMA Open to Discuss Use of Complementary Methodologies for Rare Cancers
By European Society for Medical Oncology
On 3 October 2014, the European Medicines Agency (EMA) hosted a meeting with representatives of Rare Cancers Europe (RCE) to discuss RCE's recent publication of a consensus paper on …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition